W. Nathaniel Brennen, Ph.D.

William Nathaniel Brennen, Ph.D.

Headshot of W. Nathaniel Brennen
  • Associate Professor of Oncology

Research Interests

Prostate Cancer; Therapy; Tumor Microenvironment; Fibroblasts; MSCs; prodrugs; Stroma ...read more

Background

Titles

  • Associate Professor of Oncology
  • Associate Professor of Pharmacology and Molecular Sciences
  • Associate Professor of Urology

Departments / Divisions

Education

Degrees

  • Ph.D.; Johns Hopkins University School of Medicine (Maryland) (2011)
  • B.A.; University of Delaware (Delaware) (2002)

Research & Publications

Selected Publications

View all on PubMed

WN Brennen, JT Isaacs, SR Denmeade, Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular cancer therapeutics 11 (2), 257-266

WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade, Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute 104 (17), 1320-1334

Y Zhu, SL Dalrymple, I Coleman, SL Zheng, J Xu, JE Hooper, et al. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene 39 (45), 6935-6949

WN Brennen, Y Zhu, IM Coleman, SL Dalrymple, L Antony, RA Patel, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI insight 6 (8)

TEG Krueger, DLJ Thorek, SR Denmeade, JT Isaacs, WN Brennen. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem cells translational medicine 7 (9), 651-663

Is this you? Edit Profile
back to top button